Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC trial.

Int J Colorectal Dis · 2024 · PMC11166830 · PMID 38862615

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Comparisons focusing on GWMS showed a trend toward a higher rate of rectal cancer in the LMCC group, whereas comparisons of other parameters revealed no significant differences between the two groups.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.